Oklahoma Firefighters Pension and Retirement System v. Biogen Inc. et al
Case Number:
1:22-cv-10200
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
October 07, 2025
Biogen Says Investors Can't Expand Alzheimer's Drug Suit
Biogen Inc. said a class of investors suing over alleged misleading statements in connection with the rollout of the company's Alzheimer's drug should not be allowed to needlessly delay resolution by filing an amended complaint expanding the class period and adding new legal theories and claims.
-
February 04, 2025
Judge Explains Biogen Class Cert. Ruling After 1st Circ. Order
A Massachusetts federal judge on Tuesday said he was reminded of a grade school lesson in long division as he explained his reasoning behind granting class certification and cutting short the class period in a suit against drugmaker Biogen Inc. on the orders of the First Circuit.
-
May 13, 2024
Biogen Investors Seek Class Cert. In Alzheimer's Drug Suit
A proposed class of Biogen shareholders urged a Massachusetts federal court to certify their now-revived class action alleging the drugmaker made misleading statements about a deficient Alzheimer's drug, arguing it can sufficiently lead the suit with Block & Leviton LLP as class counsel.
-
March 29, 2023
Biogen Judge Tosses Investor Suit, Calling It 'House Of Cards'
A Massachusetts federal judge tossed a suit Wednesday brought by shareholders accusing Biogen of making misleading statements about a deficient Alzheimer's drug, ruling the complaint is a "house of cards" full of mischaracterizations.
-
July 28, 2022
Biogen Denies Misleading Investors Over Alzheimer's Drug
Healthcare giant Biogen denied making any misleading statements to its investors Wednesday in a motion to dismiss a securities class action alleging the company knew an Alzheimer's drug was deficient but went ahead with its production anyway.
-
February 08, 2022
Biogen Hid Issues With Alzheimer's Drug, Investor Suit Claims
Biogen was hit with a proposed class action Monday from investors whose shares plummeted after a controversial new Alzheimer's drug failed to deliver the financial gains they expected.